Non-steroidal anti-inflammatory drugs in cancer prevention and therapy

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3147-3162

  Guadagni, Fiorella ^a   Ferroni, Patrizia ^a   Palmirotta, Raffaele ^a   Del Monte, Girolamo ^b   Formica, Vincenzo ^b   Roselli, Mario ^b,c  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cancer therapy; Cyclooxygenase cancer prevention; NSAIDs; Review

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; EXEMESTANE; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; LETROZOLE; LUMIRACOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PLACEBO; ROFECOXIB; SULINDAC; VALDECOXIB;

ADENOMATOUS POLYP; ADJUVANT THERAPY; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL ADENOMA; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEART DEATH; HEART FAILURE; HEART INFARCTION; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; HUMANS; NEOPLASMS;

EID: 35348956422     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Kune GA, Kune S and Watson LF: Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399-4404, 1988.
2. Yona D and Arber JN: Coxibs and cancer prevention. Cardiovasc Pharmacol 47: S76-S81, 2006.
3. Thun MJ, Henley SJ and Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266, 2002.
4. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
5. Alberts DS, Potter JD, Martinez ME, Hess LM, Stopeck A and Lance P: What happened to the coxibs on the way to the cardiologist? Cancer Epidemiol Biomarkers Prev 14: 555-556, 2005.
6. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (London) 231: 232-235, 1971.
7. Fu JY, Masferrer JL, Seibert K, Raz A and Needleman P: The induction and suppression of prostaglandin H2 synthase (cylooxygenase) in human monocytes. J Biol Chem 265: 1727-1740, 1990.
8. Jones D, Carlton D, McIntyre T, Zimmerman GA and Prescott SM: Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 268: 9049-9054, 1993.
9. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
10. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS and Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/ antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926-13931, 2002.
11. Hersh EV, Lally ET and Moore PA: Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray? Curr Med Res Opin 21: 1217-1226, 2005.
12. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1299: 125-140, 1996.
13. Kulmacz RJ: Cellular regulation of prostaglandin H synthase catalysis. FEBS Lett 430: 154-157, 1998.
14. Chen W, Pawelek TR and Kulmacz RJ: Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and -2. J Biol Chem 274: 20301-20306, 1999.
15. FitzGerald GA and Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345: 433-442, 2001.
16. Patrono C: The PGH-synthase system and isozyme-selective inhibition. J Cardiovasc Pharmacol 47: S1-6, 2006.
17. Peterson WL and Cryer B: COX-1-sparing NSAIDs - is the enthusiasm justified? JAMA 282: 1961-1963, 1999.
18. Willoughby DA, Moore AR and Colville-Nash PR: COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 355: 646-648, 2000.
19. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA and Vane JR: Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96: 7563-7568, 1999.
20. Stacy ZA, Dobesh PP and Trujillo TC: Cardiovascular risks of cyclooxygenase inhibition. Pharmacotherapy 26: 919-938, 2006.
21. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H and Taubert KA: Use of nonsteroidal antiinflammatory drugs. An update for clinicians. A Scientific Statement from the American Heart Association. Circulation 115: 1634-1642, 2007.
22. Vane JR, Bakhle YS and Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120, 1998.
23. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK and Schnitzer TJ; VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528, 2000.
24. Anderson WF, Umar A, Viner JL and Hawk ET: The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 8: 1035-1062, 2002.
25. Bresalier RS, Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA and Baron JA: Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005.
26. Steffel J, Lüscher TF, Ruschitzka F and Tanner FC: Cyclooxygenase-2 inhibition and coagulation. J Cardiovasc Pharmacol 47: S15-S20, 2006.
27. Marwali MR and Mehta JL: COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies. Thromb Haemost 96: 401-406, 2006.
28. James MJ and Cleland LG: Cyclooxygenase-2 inhibitors: what went wrong? Curr Opin Clin Nutr Metab Care 9: 89-94, 2006.
29. Ulrich CM, Bigler J and Potter JD: Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Rev Cancer 6: 131-140, 2006.
30. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
31. Macarthur M, Hold GL and El-Omar EM: Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286: G515-G520, 2004.
32. Rigas B, Goldman IS and Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518-523, 1993.
33. Uefuji K, Ichikura T and Mochizuki H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 6: 135-138, 2000.
34. Rolland PH, Martin PM, Jacquemier J, Rolland AM and Toga M: Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64: 1061-1070, 1980.
35. Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K and Nukiwa T: Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62: 63-66, 2002.
36. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB and Whelan J: Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 62: 403-408, 2002.
37. Kawamori T, Uchiya N, Sugimura T and Wakabayashi K: Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24: 985-990, 2003.
38. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK and DuBois RN: Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferators activated receptor delta. Cancer Cell 6: 285-295, 2004.
39. Wang D and DuBois RN: Prostaglandins and cancer. Gut 55: 115-122, 2006.
40. Watanabe K, Kawamori T, Nakatsugi S, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T and Wakabayashi K: Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093-5096, 1999.
41. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T and Wakabayashi K: Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 62: 28-32, 2002.
42. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M and Taketo MM: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcDelta716 knockout mice. Nat Med 7: 1048-1051, 2001.
43. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF and Hla T: Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101: 591-596, 2004.
44. Kawamori T, Uchiya N, Nakatsugi S, Watanabe K, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Sugimura T and Wakabayashi K: Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis 22: 2001-2004, 2001.
45. Sheng H, Shao J, Washington MK and DuBois RN: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075-18081, 2001.
46. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D and Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8: 289-293, 2002.
47. Kage K, Fujita N, Oh-hara T, Ogata E, Fujita T and Tsuruo T: Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. Biochem Biophys Res Commun 254: 259-263, 1999.
48. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK and DuBois RN: Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10: 245-247, 2004.
49. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998.
50. Poligone B and Baldwin AS: Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J Biol Chem 276: 38658-38664, 2001.
51. Yoshimoto T, Takahashi Y, Kinoshita T, Sakashita T, Inoue H and Tanabe T: Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase overexpressing human colon carcinoma cells. Adv Exp Med Biol 507: 403-407, 2002.
52. Buchanan FG, Wang D, Bargiacchi F and DuBois RN: Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278: 35451-35457, 2003.
53. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P and Discafani CM: Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024-1028, 2000.
54. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM and Bertagnolli MM: Apc deficiency is associated with increased EGFR activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 279: 43261-43272, 2004.
55. Husain SS, Szabo IL, Pai R, Soreghan B, Jones MK and Tarnawski AS: MAPK (ERK2) kinase - a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth. Life Sci 69: 3045-3054, 2001.
56. Wang D, Buchanan FG, Wang H, Dey SK and DuBois RN: Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65: 1822-1829, 2005.
57. Langenbach R: Cyclooxygenase-1 and cyclooxygenase-2 knockout mice provide insights into beneficial and adverse effects of nonsteroidal anti-inflammatory drugs. In: COX-2 Blockade in Cancer Prevention and Therapy. Harris RE (ed.). Totowa, Humana Press pp. 147-155, 2002.
58. Harris RE, Beebe-Donk J, Doss H and Burr Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of nonselective COX-2 blockade. Oncol Rep 13: 559-583, 2005.
59. Grösch S, Jürgen Maier T, Schiffmann S and Geisslinger G: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98: 736-747, 2006.
60. Grösch S, Tegeder I, Niederberger E, Bräutigam L and Geisslinger G: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15: 2742-2744, 2001.
61. Maier TJ, Schilling K, Schmidt R, Geisslinger G and Grosch S: Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67: 1469-1478, 2004.
62. Lin HP, Kulp SK, Tseng PH, Yang YT, Yang CC and Chen CS: Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther 3: 1671-1680, 2004.
63. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ and Chen CS: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64: 1444-1451, 2004.
64. Lim ML, Lum MG, Hansen TM, Roucou X and Nagley P: On the release of cytochrome c from mitochondria during cell death signaling. J Biomed Sci 9: 488-506, 2002.
65. Jendrossek V, Handrick R and Belka C: Celecoxib activates a novel mitochondrial apoptosis signaling pathway. Faseb J 17: 1547-1549, 2003.
66. Dandekar DS, Lopez M, Carey RI and Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 115: 484-492, 2005.
67. Ruvolo PP: Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 47: 383-392, 2003.
68. 2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 366: 831-837, 2002.
69. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM and Lippman SM: The 15-lipoxygenase-1 product 13-5-hydroxyoctadecadienoic acid downregulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA 100: 9968-9973, 2003.
70. Joon Baek S and Eling TE: Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog Lipid Res 45: 1-16, 2006.
71. Eling TE, Joon Baek S, Shim M and Ho Lee C: NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 39: 649-655, 2006.
72. Ostrowski J, Wocial T, Skurzak H and Bartnik W: Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors? Br J Cancer 88: 1143-1151, 2003.
73. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64: 2030-2038, 2004.
74. Wadell WR and Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24: 83-87, 1983.
75. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R and Fraumeni JF Jr: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307-311, 1993.
76. Thun MJ, Namboodiri MM and Heath CJ Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
77. Schreinemachers DM and Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146, 1994.
78. Langman MJ, Cheng KK, Gilman EA and Lancashire RJ: Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320: 1642-1646, 2000.
79. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr and Blot WJ: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7: 97-102, 1998.
80. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF and Hanley JA: Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83: 112-120, 2000.
81. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC and Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82: 1364-1369, 2000.
82. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR and Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993.
83. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJ and Hamilton SR: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346: 1054-1059, 2002.
84. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
85. Sandler RS, Halabi S, Baron JA, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F and van Stolk RU: A randomized trial of aspirin to prevent colorectal adenomas in subjects with previous colorectal cancer. N Engl J Med 348: 883-890, 2003.
86. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F and van Stolk RU. 1: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899, 2003.
87. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y and Frazier ML: Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 117: 350-358, 1999.
88. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A and Willett WC: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Int Med 121: 241-246, 1994.
89. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC and Speizer FE: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609-614, 1995.
90. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E and Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080, 2005.
91. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD and Levin B: PreSAP Trial Investigators: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885-895, 2006.
92. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Lofrus S and Morton DG: APPROVe Trial Investigators: APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131: 1674-1682, 2006.
93. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Code D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB and Hawk ET: APC Study Investigators: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873-884, 2006.
94. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N and Wittes J: APC and PreSAP Trial Investigators: Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114: 1028-1035, 2006.
95. Larkins TL, Nowell M, Singh S and Sanford GL: Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 6: 181, 2006.
96. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI and Santella RM: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs and breast cancer risk. Breast Cancer Res 8: R71, 2006.
97. Yoshinaka R, Shibata MA, Morimoto J, Tanigawa N and Otsuki Y: COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res 26: 4245-4254, 2006.
98. McFadden DW, Riggs DR, Jackson BJ and Cunningham C: Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro. Int J Oncol 29: 1019-1023, 2006.
99. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ and Neugut AI: Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291: 2433-2440, 2004.
100. Pereg D and Lishner M: Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 258: 115-123, 2005.
101. Chow LW, Wong JL and Toi ML: Celecoxib anti-aromatase neoadjuvant trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol 86: 443-447, 2003.
102. Canney PA, Machin MA and Curto J: A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Eur J Cancer 42: 2751-2756, 2006.
103. Howe LR, Subbaramaiah K, Patel J Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM and Dannenberg AJ: Celecoxib, a selective cyclooxygenase inhibitor, protects against human epidermal growth factor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62: 5405-5407, 2002.
104. Teicher BA, Korbut TT, Menon K, Holden SA and Ara G: Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol 33: 515-522, 1994.
105. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA and Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-6184, 1999.
106. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M and Takahashi T: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6: 2006-2011, 2000.
107. Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, Whitehead CM, Piazza G, Pamukcu R, Thompson WJ, Alila H, Nelson P and Bunn PA Jr: Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res 8: 904-912, 2002.
108. Harris RE, Beebe-Donk J and Schuller HM: Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 9: 693-695, 2002.
109. Muscat JE, Chen SQ, Richie Jr JP Altorki NK, Citron M, Olson S, Neugut AI and Stellman SD: Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer 97: 1732- 1736, 2003.
110. Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP and Johnson DH: Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 11: 6634-6640, 2005.
111. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW and Dannenberg AJ: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21: 2645-2650, 2003.
112. Narayanan BA, Narayanan NK, Pttman B and Reddy BS: Adenocarcinoma of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 66: 257-265, 2006.
113. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P and Mukhtar H: Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64: 3334-3343, 2004.
114. Menezes RJ, Swede H, Niles R and Moysich KB: Regular use of aspirin and prostate cancer risk. Cancer Causes Control 17: 251- 256, 2006.
115. Bosetti C, Talamini R, Negri E, Franceschi S, Montella M and La Vecchia C: Aspirin and risk of prostate cancer. Eur J Canc Prev 15: 43-45, 2006.
116. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC and Giovannucci E: Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 11: 1108-1111, 2002.
117. Habel LA, Zaho W and Stanford JL: Daily aspirin use and prostate cancer risk in a large multiracial cohort in the US. Cancer Causes Control 13: 427-434, 2002.
118. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM and Jacobsen SJ: A population based study of daily non steroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 77: 219-225, 2002.
119. Mahmud SM, Tanguay S, Begin LR, Franco EL and Aprikian AG: Non steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 15: 158-164, 2006.
120. Irani J, Ravery V, Pariente JL Chartier-Kastler E, Lechevallier E, Soulie M, Chautard D, Coloby P, Fontaine E, Bladou F, Desgrandchamps F and Haillot O: Effect of non steroidal antiinflammatory agents and finasteride on prostate cancer risk. J Urol 168: 1985-1988, 2002.
121. Royle JS, Ross JA, Ansell I, Bollina P, Tuloch DN and Habib FK: Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3. J Urol 172: 338-344, 2004.
122. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ and Kantoff PW: Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 24: 2723-2728, 2006.
123. DuBois RN: Cyclooxygenase-2 selective-inhibitors and prostate cancer: What is the clinical benefit. J Clin Oncol 24: 2691-1693, 2006.
124. Feldman M and McMahon AT: Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 132: 134-143, 2000.
125. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106: 13S-24S, 1999.
126. Howard PA and Delafontaine P: Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 43: 519-525, 2004.
127. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E and Gertz BJ: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104: 2280-2288, 2001.
128. Weir MR, Sperling RS, Reicin A and Gertz BJ: Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 146: 591-604, 2003.
129. Solomon DH, Glynn RJ, Levin R and Avorn J: Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 162: 1099-1104, 2002.
130. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H and Avorn J: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068-2073, 2004.
131. Strand V and Hochberg MC: The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 47: 349-355, 2002.
132. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A and Stukel TA: Cyclooxygenase-2 inhibitors versus nonselective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363: 1751-1756, 2004.
133. Whelton A, White WB, Bello AE, Puma JA and Fort JG: SUCCESS-VII Investigators: Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90: 959-963, 2002.
134. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Pure E, Lawson JA and FitzGerald GA: Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111: 334-342, 2005.
135. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ and Chesebro JH; TARGET Study Group: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364: 675-684, 2004.
136. Reicin AS, Shapiro D, Sperling RS, Barr E and Yu Q: Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 89: 204-209, 2002.
137. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC and Laupacis A: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 163: 481-486, 2003.
138. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG and Griffin MR: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360: 1071-1073, 2002.
139. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S and Ray WA: Risk of acute myocardial infraction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475- 481, 2005.
140. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA and Egger M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364: 2021-2029, 2004.
141. Rahme E, Pilote L and LeLorier J: Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 162: 1111-1115, 2002.
142. Watson DJ, Rhodes T, Cai B and Guess HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 162: 1105-1110, 2002.